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Abstract
A central tenet in support of research reproducibility is the ability to uniquely
identify research resources, i.e., reagents, tools, and materials that are used to
perform experiments. However, current reporting practices for research
resources are insufficient to allow humans and algorithms to identify the exact
resources that are reported or answer basic questions such as “What other
studies used resource X?” To address this issue, the Resource Identification
Initiative was launched as a pilot project to improve the reporting standards for
research resources in the methods sections of papers and thereby improve
identifiability and reproducibility. The pilot engaged over 25 biomedical journal
editors from most major publishers, as well as scientists and funding officials.
Authors were asked to include Research Resource Identifiers (RRIDs) in their
manuscripts prior to publication for three resource types: antibodies, model
organisms, and tools (including software and databases). RRIDs represent
accession numbers assigned by an authoritative database, e.g., the model
organism databases, for each type of resource. To make it easier for authors to
obtain RRIDs, resources were aggregated from the appropriate databases and
their RRIDs made available in a central web portal (
). RRIDs meet three key criteria: they arewww.scicrunch.org/resources
machine readable, free to generate and access, and are consistent across
publishers and journals. The pilot was launched in February of 2014 and over
300 papers have appeared that report RRIDs. The number of journals
participating has expanded from the original 25 to more than 40. Here, we
present an overview of the pilot project and its outcomes to date. We show that
authors are generally accurate in performing the task of identifying resources
and supportive of the goals of the project. We also show that identifiability of
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and supportive of the goals of the project. We also show that identifiability of
the resources pre- and post-pilot showed a dramatic improvement for all three
resource types, suggesting that the project has had a significant impact on
reproducibility relating to research resources.
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            Amendments from Version 1
The main update of the paper centers on a reanalysis of 
‘correctness’ of resources as shown in New Figure 3 and 
importantly the supplemental data files. The reanalysis was done 
to standardize our approach with the data scientist framework 
to address the question whether authors were correct in adding 
identifiers to their papers. The accepted measure in data 
science publications is to assess correct identification as a True 
Positive or True Negative and incorrectness as a False Positive 
or False Negative. These definitions are standard and can be 
more easily interpreted. This is a more granular approach to 
assessing whether authors could accomplish the task in the RII 
pilot project in a manner consistent with the ability to reuse the 
data (utility section) and all raw data has been included in the 
supplementary file. Relevant sections describing the correctness, 
and implications of this were updated. While the analysis was 
fairly involved and was redone almost from scratch, on the whole 
the results are not substantially different and the final answer 
remains that data scientists will not get as much from the RII as 
authors looking for reagents. 
See referee reports
REVISED
Editorial Note
A version of this article is also available in Journal of Comparative 
Neurology (doi: 10.1002/cne.23913), Brain and Behavior (doi: 
10.1002/brb3.417) and NeuroInformatics (doi: 10.1007/s12021-
015-9284-3).
Introduction
Research resources; defined here as the reagents, materials, and 
tools used to produce the findings of a study; are the cornerstone of 
biomedical research. However, as has long been bemoaned by data-
base curators and investigated by Vasilevsky and colleagues, it is 
difficult to uniquely identify these resources in the scientific litera-
ture (Vasilevsky et al., 2013). This study found that researchers did 
not include sufficient detail for unique identification of several key 
research resources, including model organisms, cell lines, plasmids, 
knockdown reagents or antibodies. In most cases, authors provided 
insufficient metadata about the resource to conclusively identify 
the particular resource, e.g., a non-unique set of attributes with no 
catalog or stock number. It should be noted that the authors were, 
generally speaking, following the reporting guidelines offered by 
the journals. Such guidelines traditionally state that authors should 
include the company name and city in which it was located for the 
resources used in the study. Further, even when uniquely identifying 
information was provided (e.g., a catalog number for a particular 
antibody), the vendor may have gone out of business, the particular 
product may no longer be available, or its catalog information may 
have changed. Given that in these cases a human cannot find which 
resources were used, an automated agent, such as a search engine or 
text mining tools will also not be able to identify the resources.
Because current practices for reporting research resources within 
the literature are inadequate, non-standardized, and not optimized 
for machine-readable access, it is currently very difficult to answer 
very basic questions about published studies such as “What studies 
used the transgenic mouse I am interested in?” These types of ques-
tions are of interest to the biomedical community, which relies on 
the published literature to identify appropriate reagents, troubleshoot 
experiments, and aggregate information about a particular organ-
ism or reagent to form hypotheses about mechanism and function. 
Such information is also critical to funding agencies that funded 
a research group to generate a particular tool or reagent; and the 
resource providers, both commercial and academic, who would 
like to be able to track the use of these resources in the literature. 
Beyond this basic utility, identification of the particular research 
resource used is an important component of scientific reproducibil-
ity or lack thereof.
The Resource Identification Initiative (RII) is laying the foundation 
of a system for reporting research resources in the biomedical lit-
erature that will support unique identification of research resources 
used within a particular study. The initiative is jointly led by the 
Neuroscience Information Framework (NIF; http://neuinfo.org) and 
the Oregon Health & Science University (OHSU) Library, data inte-
gration efforts occurring as part of the Monarch Initiative (www.
monarchinitiative.org), and with numerous community members 
through FORCE11, the Future of Research Communications and 
e-Scholarship, which is a grassroots organization dedicated to trans-
forming scholarly communication through technology. Since 2006, 
NIF has worked to identify research resources of relevance to neuro-
science. The OHSU group has long-standing ties to the model organ-
ism community, which maintains databases populated by curating 
the literature and contacting authors to add links between model 
organisms, reagents, and other data. In a 2011 workshop (see https://
www.force11.org/node/4145) held under the auspices of the Linking 
Animal Models to Human Diseases (LAMHDI) consortium, various 
stakeholders from this community drafted recommendations for bet-
ter reporting standards for animal models, genes, and key reagents.
The RII initiative was launched as a result of two planning meetings 
building off of the recommendations of the LAMHDI workshop. 
The first was held in 2012 at the Society for Neuroscience meeting 
with over 40 participants comprising editors, publishers and funders 
(sponsored by INCF; http://incf.org). This meeting outlined the 
problem of incomplete identification of research resources within 
papers, and the need for a computational solution for identifying and 
tracking them in the literature. Recognizing that any solution needed 
to work for both humans and machines, three broad requirements 
were identified: 1) the standard should be machine-processable, 
that is, designed for search algorithms, in addition to human under-
standing; 2) the information should be available outside the pay 
wall, so that search algorithms and humans have free access to the 
information across the biomedical literature; and 3) the standard 
should be uniform across publishers, to make uptake and usage 
easier for both human and machines.
A follow-up workshop at the NIH (https://www.force11.org/
node/4857) was held in June of 2013 to gain agreement from this 
stakeholder group for the design of a pilot that would explore solu-
tions for this problem. A working group, the Resource Identifica-
tion Initiative, was established through FORCE11 comprised of 
publishers, journal editors, antibody manufacturers and distributors, 
biocurators, software tool developers, and foundations. Based upon 
agreements garnered at the June 2013 meeting, the RII designed a 
pilot project to test implementation of a system for authors submit-
ting manuscripts to identify research resources through the use of a 
unique identifier, termed a Research Resource Identifier (RRID).
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Pilot project overview
The pilot project limited its focus to three types of resources - 
primary antibodies, non-commercial software tools/databases, and 
model organisms. These were chosen because they are a major 
source of variation across experiments and are used broadly across 
biomedical research communities. For the purposes of this pilot, 
a critical aspect was that a relatively complete and authoritative 
central registry existed that could issue an accession number, as 
GenBank does for gene sequences. To gain broad agreement 
amongst publishers and editors who were concerned about the 
potential burden on authors and staff, it was agreed that participa-
tion in the pilot project would be voluntary for authors with partici-
pation not representing a condition of acceptance for publication. 
The pilot project was also designed to have minimal requirements 
for publishers such that modification of manuscript submission 
systems was not required.
The pilot project was originally designed to run for 6 months, with 
each of the participating journals agreeing to participate for at least 
3 months. The goal was to ensure a large enough sample to under-
stand author behavior: could they and would they do the task, and 
to obtain sufficiently large participation to demonstrate the utility of 
RRIDs. Over the minimum 3-month window, each partner journal 
would request authors to supply RRIDs in a standard format as a 
citation to indicate the use of antibodies, software and databases, 
and model organisms. To be as unambiguous as possible, authors 
were to include the RRIDs for resources that were utilized in the 
study and described in the text of the materials and methods, but 
not in the introduction or discussion sections where they might be 
mentioned in passing but not used in the study. The RRID syntax 
comprises an accession number assigned by the authoritative data-
base with the prefix “RRID:” prepended (e.g., RRID:AB_2298772 
for an antibody). We also requested that non open-source journals 
include RRIDs in the keyword field, as this field is available for 
indexing in PubMed outside of paywalls. The journals were given 
flexibility for when and how they wanted to ask authors for these 
identifiers, namely, at time of submission, during review, or after 
acceptance. They were not required to modify their instructions to 
authors or their submission systems. The RII team would be respon-
sible for preparing appropriate materials for requesting RRIDs and 
for establishing a central portal where these identifiers could be 
obtained. The RII team also agreed to establish a help desk to assist 
the authors if they encountered any difficulties.
The pilot project was designed to address four key questions. A set 
of evaluation criteria was designed for each question: 
1.   Participation: Would authors be willing to add resource 
identifiers to their publications and register new resources 
in the system? Participation was evaluated by examining the 
number of submissions to the participating journals, the rate 
of author participation in providing RRIDs, the number of 
new resources registered, and direct feedback from authors.
2.   Performance: Could authors add these identifiers correctly 
or would additional editorial or staff oversight be neces-
sary? Performance was measured by a quantitative analysis 
of RRID correctness by RII curators.
3.   Identifiability: Would the use of RRIDs improve our abil-
ity to identify resources in the literature? Identifiability was 
measured both pre- and post-pilot in the journals that par-
ticipated.
4.   Utility: Will RRID’s be useful to the scientific community? 
Can the RRID’s as constructed be used to identify all stud-
ies that use a particular research resource? To encourage 
the development of applications, the data set is being made 
freely available so that third parties can develop tools to 
work with RRIDs.
The pilot began in February 2014, with over 25 journals participat-
ing. Journals that sent a letter to authors at some stage of the review 
process included: Journal of Neuroscience, Brain and Behavior, 
Journal of Comparative Neurology, Brain Research, Experimental 
Neurology, F1000Research, PeerJ, Journal of Neuroscience Meth-
ods, Neurobiology of Disease, and the Frontiers group of journals. 
One journal, Neuroinformatics, chose to add the RRIDs to all manu-
scripts before asking authors to do this. Journals in the Elsevier and 
BMC groups were participants based upon updates to their instruc-
tions to authors. Because of the success of the project, it was subse-
quently extended and is still active as of this writing. The number of 
journals participating has expanded, and now includes PLoS Biol-
ogy and PLoS Genetics as well as multiple immunology journals in 
the Elsevier family. A list of the participating journals is available 
on the Force11 website (https://www.force11.org/RII/SignUp).
One of the primary requirements of the pilot project was to make it 
as easy as possible for authors to obtain the appropriate identifiers 
and insert them correctly into their manuscripts. As noted above, 
the three research resources were chosen because each was covered 
by an authoritative database (Table 1) that assigned unique IDs and 
a standard set of metadata to each. However, as can be seen by the 
length of the list in Table 1, authors could potentially be required to 
visit several databases to obtain the appropriate identifiers.
To simplify this process, we established a Resource Identification 
Portal based upon the SciCrunch platform, which leverages data 
aggregation performed by the DISCO aggregation engine (Marenco 
et al., 2014; http://scicrunch.org/resources; Figure 1). The portal 
provides a unified query across different resource databases and dis-
played the results in a common format. The portal allows search on 
various facets such as resource name, catalog number, etc. There is 
a ‘cite this’ link that provides the citation, as it should be reported in 
the paper. The citation generally includes not just the RRID, but a set 
of appropriate metadata that would identify the vendor and catalog 
number as well, for example: A polyclonal antibody against tyrosine 
hydroxylase (TH) (Chemicon, Cat. AB1542, RRID:AB_90755).
To simplify this process, we utilized the data aggregation services of 
the NIF, provided through a platform known as SciCrunch, to estab-
lish a Resource Identification Portal (http://scicrunch.org/resources; 
Figure 1). The portal provided a unified query across these different 
databases and displayed the results in a common format. The por-
tal allows search on various facets such as resource name, catalog 
number, etc. There is a ‘cite this’ link that provides the citation as it 
should be reported in the paper. The citation generally includes not 
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just the RRID, but a set of appropriate metadata that would identify 
the vendor and catalog number as well, for example: A polyclo-
nal antibody against tyrosine hydroxylase (TH) (Chemicon, Cat. 
AB1542, RRID:AB_90755).
Methods
SciCrunch was built based on the extensible Neuroscience Infor-
mation Framework platform described previously (Gardner et al., 
2008; Marenco et al., 2014; RRID:nif-0000-25673), and the portal 
infrastructure for RII was developed under an award from NIDDK 
to create a dkNET portal (RRID:nlx_153866), while the customiza-
tion of the portal was done by Monarch staff. The data is aggregated 
from the SciCrunch tool registry, the antibody registry, as well as the 
model organism community databases and stock centers (Table 1). 
The data infrastructure allows curators to keep indexes synchro-
nized with the source databases by using an automated crawling 
engine and new data are released on a weekly basis. All open data 
from each of these databases is available to download from the 
source sites, where update frequencies are listed.
The journal editors were provided with recommended instruc-
tions to authors (the instructions to authors are available here: 
https://www.force11.org/node/4856). For antibodies, we only 
required authors to identify primary antibodies and not secondary 
or tertiary complexes. For software tools and databases we focused 
on freely available and generally publicly funded non-commercial 
tools. For model organisms, we focused on the five commonly used 
organisms: mouse, rat, zebrafish, fruit fly, and worm. Authors were 
asked to insert the correct citation for the resource into the text of 
the materials and methods section and in the keywords. A help desk 
was established by the RII working group that provided help if an 
author encountered difficulty. In most cases, requests were handled 
in less than 24 hours.
If a resource was not found via the portal, authors were given the 
option to submit the resource to obtain an identifier. For antibodies 
and software/databases, which are found in databases maintained 
within the NIF, submission was handled through the Resource 
Identification Portal. For model organisms, the author was referred 
to the authoritative model organism database for their organism 
(RGD, MGI, ZFIN, Wormbase, or Flybase). All new submissions 
were curated by their respective databases and the data was pulled 
back into the RII portal weekly so that authors could see their newly 
registered resources in approximately a week.
Figure  1. The Resource  Identification  Initiative  portal  containing  citable  Research Resource  Identifiers  (RRIDs).  The workflow for 
authors is to visit http://scicrunch.org/resources, then select their resource type (see community resources box), type in search terms (note 
that the system attempts to expand known synonyms to improve search results) and open the “Cite This” dialog box. The dialog shown here 
displays the Invitrogen catalog number 80021 antibody with the RRID:AB_86329. The authors are asked to copy and paste this text into their 
methods section.
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To evaluate the aims of the pilot project, we tracked the use of 
RRIDs in published papers and journals. We performed an in depth 
analysis of the first 100 papers found through Google Scholar that 
reported RRID’s. For each paper, we examined the methods sec-
tion to determine the correct usage (i.e. if the RRID pointed to 
the correct resource), the syntactic correctness (i.e. if the author 
reported the RRID using the correct syntax), and the identifiability 
of the three resource types. The total number of research resources 
reported in the first 100 papers reporting RRIDs was determined 
by manual inspection of each paper by two independent curators. 
A Google Scholar alert was used to track all new papers that con-
tained an RRID, using the search “RRID:”. Each of the first 100 
papers was downloaded and examined for the snippets of text sur-
rounding research resources (in the methods or data use sections).
Curation workflow to determine correct usage of reported 
RRIDs
To determine if the RRIDs were reported correctly for the three 
resource types, the following criteria was applied.
•    A resource was considered correct if resource reported an 
RRID and that RRID pointed to the correct resource in the 
RII portal. This determination was made both by manual 
search of the RII portal and via the SciCrunch resolving serv-
ice for each reported RRID (for example, https://scicrunch.
org/resolver/RRID:AB_262044).
•    A resource was considered incorrect if the reported RRID 
pointed to a different or non-exising resource in the RII portal 
or SciCrunch resolving service.
•    A resource was considered to have the correct syntax if the 
resource reference contained an RRID, and the RRID was for-
matted correctly, had no missing characters or other typos.
Curation workflow for identifiability of the three resource types
To determine if the three resource types were identifiable in the 
journal articles that reported RRIDs (post-pilot), and in articles 
from the same journals before the pilot started. To select the pre-
pilot articles, articles were selected by performing a PubMed search 
filtered for each journal and using the first five publications returned 
that contained the relevant resource types from approximately 
January–March 2013. The following criteria were applied: 
Resources (primary antibodies, organisms, and non-commercial 
tools) were considered identifiable if they contained an accurate 
RRID or by using the same specific resource identification criteria 
as described in Vasilevsky et al. (2013). Non-commercial software 
and databases that were not previously analyzed were considered 
identifiable if they contained the correct RRID or reported the man-
ufacturer and version number for that tool. Note we distinguished 
commercially produced for-profit software from public or individu-
ally produced software (non-commercial).
Statistical analysis for identifiability of the three resources
Since the data was binomial in that each resource was either iden-
tifiable or not, we used a binomial confidence interval strategy for 
calculating upper and lower 95% confidence intervals (CI) (http://
www.danielsoper.com/statcalc3/calc.aspx?id=85, RRID:SCR_
013827). Error bars for the corresponding 95% CI are displayed on 
the graphs. Statistical significance was determined by calculating 
the z-score.
Table 1. Source databases and registries included in the RII portal. Each database has 
a weekly or monthly scheduled frequency of update and all new data is released weekly. If 
available, data from both model organism authorities is served as well as the list of strains 
available via particular stock centers. In most cases the stock centers maintain a link between the 
genotype and the stock center animal identifier. Scheduling and total data count information can 
be accessed via DISCO (http://disco.neuinfo.org/webportal/dataPipelineViewStatus.do?id=nlx_
154697-1).
Resource name Resource content Database Identifier
ZIRC, Zebrafish Resource Center Zebrafish Stocks RRID:nif-0000-00242
ZFIN, Zebrafish Information Network Zebrafish Nomenclature RRID:nif-0000-21427
RGD, Rat Genome Database Rat RRID:nif-0000-00134
CGC, Caenorhabditis Genetics Center Worm Stocks RRID:nif-0000-00240
WormBase Worm Nomenclature RRID:nif-0000-00053
IMSR, International Mouse Strain Resource 
Center Mouse Stocks RRID:nif-0000-09876
BDSC, Bloomington Drosophila Stock Center Fly Stocks RRID:nif-0000-00241
MGI, Mouse Genome Informatics Mouse Nomenclature RRID:nif-0000-00096
BCBC, Beta Cell Biology Consortium Mouse stocks RRID:nlx_144143
antibodyregistry.org, Antibody Registry Antibodies RRID:nif-0000-07730
SciCrunch Registry Software Tools and Databases RRID:nlx_144509
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Results
The first RRID’s began appearing in the literature in April of 2014. 
Although the first paper was identified through PubMed, the major-
ity of papers were found via Google Scholar by searching for 
“RRID”. Google Scholar, unlike PubMed, appears to search the full 
text of articles, as it returns snippets of text from the materials and 
methods containing the RRID’s (for example Figure 2). A search 
in PubMed returns very few papers, indicating that most journals 
were not including the RRIDs outside of the pay-wall. As these 
papers start to appear in PubMed Central, where full text search 
is possible, we anticipate that more papers utilizing RRIDs will 
be identifiable through the National Library of Medicine. Google 
Scholar possesses the advantage in that it obtains papers without an 
embargo period and makes them available for search immediately 
at the time of publication. In this manuscript, we therefore present 
analysis based upon Google Scholar.
Search via Google Scholar reveals that the RRID prefix is not 
a unique string, but is an acronym for several entities, mostly 
commonly the Renal Risk in Derby clinical study (for example, 
McIntyre et al., 2012). To return examples of RRIDs requires the 
use of additional filters, e.g., restricting search to the years 2014 and 
later. The combination of the RRID prefix with the resource acces-
sion number is unique however, in that searching for a particular 
RRID, for example RRID:AB_90755 returns only papers that use 
this research resource (Figure 2).
The first 100 papers were published in 16 journals and included 562 
RRIDs reported by authors. The bulk of the identifiers (490) came 
from two journals, the Journal of Comparative Neurology (JCN) 
and the Journal of Neuroscience, as these two journals were first to 
participate both starting the pilot in early February of 2014.
Outcome #1: Participation
As of March 1, 2015 there were 312 papers published with at least 
one RRID, from 44 unique journals (Supplementary Table 1 shows 
the updated list of journals and a count for each) indicating that 
hundreds of authors have participated in the pilot project even 
though it is voluntary. Table 2 shows the different mechanisms and 
timing of contact for authors by different journals. Informal feed-
back from the editors and authors via the help requests and other 
correspondence indicates that authors who are attempting to find 
RRIDs are supportive of the aims of the project and readily able to 
find the correct RRIDs.
One journal, the Journal of Neuroscience, sent authors letters asking 
authors for their participation during different periods of the publi-
cation cycle. There did not appear to be a more advantageous time 
for the correspondence. The Journal of Comparative Neurology 
directly assisted authors during different periods of the publication 
cycle and had excellent participation. The high rate of compliance 
is likely due to the direct assistance but also to the publication of 
an editorial to support awareness (Bandrowski et al., 2014) and a 
Figure 2. RRIDs found in the published literature. A. Google Scholar result for the anti-tyrosine hydroxylase antibody RRID (9/2014; http://
scholar.google.com/scholar?q=RRID:AB_90755). B. The most frequently reported RRIDs in the first 100 papers, by number of papers using 
the identifier. All data is available in the Supplementary Table and all identifiers can be accessed in Google Scholar.
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long-standing history of antibody identification back to 2006. Neu-
roinformatics has section for tools, and several papers incorporated 
RRIDs even prior to staff looking them up. The Journal of Com-
parative Neurology also has such a section and antibodies.
Authors were willing to add resources to the registries if they were 
not available. We analyzed the statistics for the Antibody Registry 
and SciCrunch Tool Registries, as we had programmatic access to 
these. Since the project began, over 200,000 antibodies from ven-
dors, both solicited and unsolicited and at least 200 from individual 
authors were added to the Antibody Registry (antibodyregistry.
org). In cases where antibodies are sold by government-led projects 
such as NeuroMab from UC Davis, antibody identifiers have been 
included in the antibody manufacturer’s website. Many of the addi-
tions were secondary antibodies, which were not part of the pilot 
project but authors felt that they should also be identified. In one 
representative example, Jackson ImmunoResearch was contacted 
by several authors and subsequently submitted their full catalog to 
the Antibody Registry, allowing authors to report RRIDs for their 
secondary antibodies. Additionally, there were over 100 software 
tools and databases registered. Many were for common commer-
cial statistical tools (e.g., SPSS, Graphpad), technically out of 
scope for the pilot project, but authors did not make the distinc-
tion between commercial and non-commercial tools. A compari-
son of new resources added versus those reported in the first 100 
papers, indicates that the Registries already listed the majority of 
research resources in each of these categories, as the number of 
new resources added for this set represented only ~10% of the total 
reported resources.
Figure 2 shows the most common tools identified by RRID in 
papers from the first 100 papers. Commercial tools such as MAT-
LAB, SAS and GraphPad were cited along with non-commercial 
tools such as ImageJ and FreeSurfer. The most common antibody 
was the anti-NeuN antibody from Millipore, now Merck. These 
same resource identifiers have continued to be very highly cited in 
subsequent papers, with ImageJ cited in 42 papers and the NeuN 
antibody cited in 8 papers (Google Scholar March 17, 2015).
Outcome #2: Performance
A major concern of the publishers and editors was whether or not 
authors could retrieve RRID’s correctly and whether significant edi-
torial oversight would be necessary for quality control (see workshop 
outcome documents at https://www.force11.org/node/4857).
To determine if authors were correctly reporting RRIDs, we ana-
lyzed the reported RRIDs, and determined if they pointed to the 
correct resources in the RII portal, by comparing the metadata and 
RRID reported for each resource using the resolving service (for 
example, see https://scicrunch.org/resolver/RRID:AB_262044) 
or by querying the portal. Overall, 96% (538/562) of the RRIDs 
reported by authors were correct (i.e., the RRID pointed to the 
correct resource). More specifically, 96% of antibodies (413/429), 
87% of organisms (48/55) and 99% of tools (77/78) were correctly 
reported (Figure 3).
Inspection of the 16 errors in reporting RRIDs for antibodies (4% 
error rate), showed that three errors were copy/paste mistakes where 
authors mixed up the combination of catalog number and identifier 
Table 2. Journal practices in contacting authors. Different journals chose to contact authors at different stages of the 
publishing cycle and assist in the addition of RRIDs via different mechanisms. The participation rate was by far the lowest 
with only instructions to authors; these journals are not included in this table (for example BMC) and had <1% participation 
rates. When authors were asked by a blanket mailing containing instructions, participation rates ranged between 1 and 
15%. Participation was very high if the editorial staff asked authors directly or suggested identifiers for their manuscript. 
Note that in some cases only an approximation could be made by the participating journals.
Journal
Number authors 
contacted during 
submission 
(mechanism)
Number authors 
contacted during 
review (mechanism)
Number authors 
contacted during 
acceptance 
(mechanism)
Participation rate
Journal of Neuroscience 1175 (letter to author) 163 (letter to author) 25 (letter to author) ~12%
Journal of Comparative 
Neurology (direct author assist) (direct author assist) (direct author assist) >90%
Brain and Behavior ~100 (letter to author) ~25%
Neuroinformatics (staff looks up RRIDs) 100%
F1000 Research ~50 (letter to author) ~12%
Brain Research 671 (letter to author) 1%
Journal of Neuroscience 
Methods 314 (letter to author) 1%
Neurobiology of Disease 291 (letter to author) 3%
Experimental Neurology 297 (letter to author) 3%
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for resources used in their paper; three errors resulted from identi-
fiers missing a digit at the end of the ID (for example, “Swant, cata-
log #6B3, RRID: AB_1000032” should have been labeled RRID: 
AB_10000320); and one error involved reporting a reference PMID 
instead of the resource identifier. The apparent cause of the other 
antibody errors was not possible to determine. For organisms, seven 
errors were made (13% error rate). All of these errors involved mice 
for which authors used the appropriate gene or allele identifier from 
Mouse Genome Informatics (MGI), rather than the stock number 
or genotype identifying the organism. It should be noted that MGI 
as of 2015 can search the genotypes, but at the time of the pilot 
project the search was limited to alleles, thus it stands to reason that 
authors went to MGI as opposed to the SciCrunch portal to iden-
tify resources. The fewest errors were made in identifying software 
tools and databases, with only one mistake from 78 total (1% error 
rate). The mistake was made as the author apparently used an anti-
body identifier instead of a tool identifier.
The use of a unique string to retrieve RRIDs is aided by a common 
syntax. In our analysis of RRIDs we also noted whether or not the 
RRID was correctly formed. In 66% (369/562) of cases, the RRID 
was reported with the correct syntax, 63% of antibodies, 85% of 
organisms, and 67% of tools were formatted correctly (Figure 3). 
The most common variant was the addition of extra spaces (RRID:
AB_90755 vs. RRID: AB_90755), with 67% (129/193) of the minor 
corrections being due to an extra space. Other common variants 
were failure to include the RRID prefix, using various symbols or 
spaces in the identifier, or splitting up the RRID prefix and identi-
fier in a table. Authors did not create RRIDs for resources they were 
either unable to find, or were not in the portal in 142 cases, which 
constitutes an overall 20% false negative rate (36/465 reported anti-
bodies were false negatives 8%, 84/139 reported organisms were 
false negatives 60%, and 22/101 tools 22% were false negatives). In 
other words, authors included RRIDs for the appropriate resource 
in over 80% of cases.
Outcome #3 Identifiability
An outcome of this study was to determine if the use of RRIDs in 
the literature increased the identifiability of research resources. As 
shown in Figure 4, when authors were asked by their editors to pro-
vide RRIDs, regardless of their compliance with the RII project, the 
identifiability of research resources significantly increased. We cal-
culated the percentage of identifiable research resources in the same 
journals, just before the pilot project and after. The reporting of 
research resources pre-pilot was consistent with findings from the 
2013 study (Vasilevsky et al., 2013), in that roughly 50–60% were 
found to be identifiable. But when asked by their editors, research-
ers used identifying information in 80–90% of research resources, 
showing that they presumably had the data available, but did not 
put it into their papers unless prompted by communication from 
the editors.
Outcome #4 Utility
Machine-processability: The ability to search all studies that used 
a particular research resource was a prime motivation for this pilot. 
The current project had a loose definition of “machine-processable” 
because we did not want to impose any requirements on the pub-
lishers to modify their journal submission system for a pilot. Thus, 
we opted to craft RRIDs as unique, indexable alphanumeric strings 
based upon authoritative sources that could support use of web 
Figure 3. Percent  correctly  reported RRIDs. The percentage of resources that reported an RRID that pointed to the correct resource 
and with the correct syntax for each resource type is shown. The total number of resources for each type during the post-pilot is: primary 
antibodies, n = 429; organisms, n = 55; non-commercial tools, n = 78.
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search engines to return papers using a particular research resource. 
We specifically asked authors to assess resources mentioned in the 
materials and methods section where they would normally provide 
identifying information, because we wanted to track actual use of 
the resource and not just mentions.
For individual RRIDs, the approach was highly successful as is 
illustrated by the ability to type a particular RRID into 3 search 
engines for the biomedical literature: Google Scholar, PubMed, 
and Science Direct and retrieve appropriate papers, e.g., RRID:
AB_90755 or AB_2298772 (for Google Scholar see Figure 2). It 
is important to note that each of these systems will come back with 
different results because each search tool has different types of data 
about each paper. For example, ScienceDirect has a good full text 
search of all Elsevier content, but it does not search other publisher’s 
content. Both PubMed and Scopus search only the abstracts and 
return a subset of articles where authors followed instructions to 
add RRIDs to the keywords, but not those that are only in the meth-
ods section. Google Scholar is the most comprehensive as it appears 
to search full text and brings back papers that are both published 
and unpublished (usually these are accepted for publication, but not 
yet indexed by PubMed). An analysis performed in October 2014 
showed varying results from each search engine: Google Scholar 
returned 315 results (from 2014, 174 are true RRIDs), and Science-
Direct returned 18 (from 2014, 3 are RRIDs). PubMed revealed 23 
papers that contained RRIDs (from 2014, all identify the resource 
identification initiative identifiers). Scopus returned 48 documents 
(from 2014, 18 are RRIDs).
To promote the development of 3rd party tools around RRID’s, 
we created a resolver service for RRIDs using SciCrunch. Typing 
http://scicrunch.com/resolver/RRID:AB_90755, will resolve to a 
landing page with meta-data on a particular entity. The resolving 
service allows applications to make use of RRIDs to, for exam-
ple, enhance articles with RRIDs by providing additional informa-
tion about the entity and link to relevant articles and resources. For 
instance, Elsevier has released their antibody application, which 
displays antibody metadata in the right hand side panel, next to 
the article (see Figure 5 for a screen shot below for (MacLaren 
et al., 2015): http://www.sciencedirect.com/science/article/pii/
S0306452214008458). The reader can browse through antibodies 
referred to in the article, view complete records in antibodyregistry.
org and access additional information via direct links to GenBank, 
ZFIN, and other relevant databases. The application also recom-
mends three most relevant articles published in Elsevier journals 
that refer to the same antibody. The application is freely available 
on ScienceDirect.
Publication practices: Non-open access journals were asked to 
add RRIDs to publication keywords, but our initial findings sug-
gest that this practice was not being consistently followed. Only 
23 papers of 41 total (as of Oct 20, 2014) were accessible in 
PubMed. Additionally it should be noted that in two cases, identi-
fiers were removed at typesetting after the initial online version 
of the manuscript was published with the RRIDs. These identi-
fiers were removed not only from the manuscript, but also from 
PubMed keywords. Although this was reversed when noted by the 
Figure  4.  Pre  and  post-pilot  identifiability. Resources (primary antibodies, organisms, and tools) were considered identifiable if they 
contained an accurate RRID or by using the same criteria as described in (Vasilevsky et al., 2013). For tools (software and databases, which 
were not previously analyzed), these resources were considered identifiable if they contained an RRID or reported the manufacturer and 
version number. The total number of resources for each type is: primary antibodies pre-pilot, n = 140; primary antibodies post-pilot, n = 465; 
organisms pre-pilot, n = 58; organisms post-pilot, n = 139; non-commercial tools pre-pilot, n = 59; non-commercial tools post-pilot, n = 101. 
The y-axis is the average percent identifiable for each resource type. Variation from this average is shown by the bars: error bars indicate 
upper and lower 95% confidence intervals. Asterisks indicate significant difference by a z-score greater than 1.96.
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working group, this demonstrates that successful implementation 
requires knowledge of the RRIDs and agreement by the publishers 
at all steps.
Discussion
The pilot RRID project has been highly successful in demonstrat-
ing the utility of a system to aid in identification of antibodies, 
software and databases, and model organisms in the biomedical lit-
erature. We showed that authors were willing to adopt new styles of 
citation for research resources that promoted more accurate iden-
tification of research resources used in a study, and that were more 
amenable to machine-based identification. To date, RRIDs have 
appeared in over 400 papers from 60 journals. With one excep-
tion (the Journal of Neuroscience), journals have continued their 
request for RRIDs beyond the initial 3-month pilot project and 
new journals have signed up beyond the initial set that started the 
project. We believe that the success of the project was due to the 
extensive pre-planning that involved the publishers and the editors, 
the limited scope of the initial request, and the recognized need 
by researchers for better and more useful reporting standards for 
research resources.
The load on curation staff with participating journals has been mini-
mal and the initial portal prototype appears reasonable for the major-
ity of authors to find their resource identifiers. With >10,000 searches 
in the RII portal, there were approximately 100 help questions. 
Many of these questions were about scope, i.e., whether a particular 
research resource should be identified, others were for assistance in 
finding a resource or guidance in adding a resource not yet contained 
in the community authorities. While this is not a large number, it is 
also not insignificant, particularly as the project expands, and cer-
tainly points out the need for specific help functions.
Given the relative completeness of the registries and the rapid 
advance of machine-learning based techniques for entity recog-
nition, we can envision a semi-automated system that assists the 
Figure 5. An exemplar third-party application using the RRID resolving service. The “Antibody data for this article” application developed 
by Elsevier enhances articles on ScienceDirect. The application is available in 211 articles in 19 journals (more information can be found at: 
http://www.elsevier.com/about/content-innovation/antibodies).
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author in supplying correct IDs. We have already improved our 
ability to detect digital research resources in the literature using 
machine learning (Ozyurt et al., in review PLoSOne). In this sys-
tem, machine learning is used to identify software tools and data-
bases in text and compare the information to Registry listings. The 
development of such functions would allow the development of 
recommender systems for authors and automated fact checkers for 
journal staff.
Why unique identifiers?
Unique identifiers serve as a primary key for identifying a given 
research resource and providing the ability for search engines to 
parse them is paramount. Unique identifiers enable disambiguation 
of entities with similar labels. The ID should not point to two dif-
ferent entities and needs to be persistent, that is, they need to outlive 
the entity itself. They also need to be at least minimally machine-
processable. While many authors supplied identifying information 
like the catalog number for an antibody supplied by the vendor, or 
the official strain nomenclature supplied by the IMSR for a mouse, 
neither of these served the required functions. A catalog number 
is not a unique identifier, but rather a useful way for vendors to 
identify their products. If different vendors sell the same antibody, 
it will have different catalog numbers. If the same antibody is sold 
in different aliquots, it may have different catalog numbers. When 
the antibody is no longer available, the catalog number may disap-
pear, or in some cases it may be reassigned to another antibody. 
All of these features are undesirable in an identifier system. The 
Antibody Registry, in contrast, was specifically designed to supply 
useful and stable identifiers for antibodies and not as a commercial 
source of antibodies. Similarly, the strain nomenclature developed 
by the Jackson Laboratory, with its superscripts and special charac-
ters, is useful for human curators to identify a particular strain, but 
causes hiccups in most search engines because of all of the special 
characters. We believe that a well-curated registry is essential to 
the success of such a system, because of the necessity of these two 
functions, which currently cannot be replaced with a simple uncu-
rated registration service. For example, we found in the registries 
we maintain, both software or antibodies, that authors sometimes 
register an entity that is found by a curator to be a duplicate.
Reporting of RRIDs
When considering accuracy and syntax, the majority of the issues 
were due to minor syntax errors (33% of RRIDs had a syn-
tax error), and a minority of the resources (4%) was incorrectly 
reported. The data suggest authors are able to find the correct 
RRID for their resource, but the higher syntax error rate indicates 
a need for an improved process for reporting the RRIDs in the 
manuscripts. The typesetting may cause some of the syntax issues, 
for example, spaces may be introduced, especially when the RRID 
is at the end of a line. Additionally, these types of syntax errors 
are resolvable by the resolver, so they do not pose an issue for the 
machine readability.
Authors included RRIDs for the appropriate resources in 80% of 
the papers. This analysis did not allow us to determine if authors did 
not report RRIDs because the resource was not available in the RII 
portal at the time, or if they failed to include the RRID for another 
reason.
The analysis for this pilot project focused on primary antibodies 
and non-commercial tools, however, many authors included RRIDs 
for secondary antibodies and commercial tools, such as MATLAB 
or SAS. While this was out of scope for this analysis, this indicates 
that authors are willing and eager to provide RRIDs for additional 
research types, not just those included in this pilot project.
In two papers, authors reported RRIDs for resources that were not 
used as part of the study, but rather were discussed in the introduc-
tion or discussion sections. A goal of this study is to enable one 
to determine the usage of a particular resource, as reported in the 
published literature. For example, one could query Google Scholar 
for all the papers that report a particular RRID to get a sense of 
how frequently that resource appears in publications. Therefore, it 
is important that only resources that are used in a study are assigned 
an RRID. This should be further clarified in the instructions to 
authors.
Which identifiers?
There are many types of and formats of identifiers in use today 
(e.g., DOIs, URIs, ARCs), each with varying amounts of associated 
infrastructure and use in different communities. For this project, we 
elected to use simple alphanumeric strings and a common syntax 
in the form of accession numbers issued by the authoritative com-
munity-based registries. We relied on each registry to impose the 
uniqueness constraint at the level of the entity, for example ensur-
ing that there was only one mouse genotype per unique ID, and 
to ensure standard metadata by curating each entry. The reuse of 
authoritative accessions with the RRID prefix provides maximal 
flexibility and interoperability and minimal ID churn, whilst also 
provisioning for resource identification.
A frequent question regarding the RRID is why we did not use a 
DOI as a unique identifier instead of the Registry Accession number. 
Part of the reason was cultural: researchers were used to supply-
ing accession numbers for Genbank, Gene Expression Omnibus, 
Protein Data Bank, etc. and understand this requirement. Part of 
the reason is practical: unlike DOIs, accession numbers are already 
available for most of the research resources to be identified in this 
pilot and did not require special infrastructure to resolve or cost 
to issue. Part of reason is also philosophical: DOIs are for digital 
objects, such as individual articles, that live on the web and need 
to be resolvable. A DOI resolves to a particular article that is self-
contained - it is the object. In contrast, an antibody does not exist on 
the web but is an independent entity that has data about it scattered 
across various articles. There is no single digital record that is the 
antibody; there are documents and data about the entity. We note 
that in our community we also do not use DOIs to identify people, 
but rather an ORCID, which serves the same purpose as the RRID.
A case could be made for using DOIs to identify particular software 
tools and databases, as they are digital objects. As discussed in the 
next section, our preference is that DOIs be used to identify the 
particular instance used, e.g., the version of data or software and 
any supporting workflows, and that the RRID be used to identify 
the entity or project referenced. Thus, the RRID would be used to 
identify the Protein Databank, and a PDB identifier or a DOI used 
to reference the specific data from the PDB. However, we believe 
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that as the RRID system is adopted, each community should set 
appropriate identifier systems. The RRID syntax is meant to be 
simple and generic and could, in theory, work with any existing 
authoritative identifier system.
How granular should RRIDs be?
RRIDs are meant to identify research resources at a fairly high 
level of granularity. At some of the planning meetings, there was a 
push for more granular information, e.g., lot and/or batch numbers 
for antibodies. We recognize that this level of granularity is likely 
an important factor in determining how a given reagent performs 
(Slotta et al., 2014). In our analysis by Vasilevsky et al. (2013) and 
in our experience using text-mining, the biggest problem is not 
that authors were not supplying lot numbers but that they are not 
even supplying the minimal identifying information such as catalog 
numbers. Given that the catalog numbers themselves do not serve 
as stable identifiers, because antibodies are bought and sold and 
redistributed by many vendors, we elected to tackle the problem 
of identifying the root antibody first, i.e., a particular clone for a 
monoclonal antibody or a type of polyclonal antibody produced by 
particular protocol. To illustrate the problem, consider the study by 
Slotta et al. (2014) that provided an analysis of the performance of 
antibodies to NF-κB-subunit p65, as a follow up to a similar study 
by Herkenham et al. (2011). Both studies performed specificity 
tests on a variety of antibodies and, as is common, did not pro-
duce concordant results on all of them. Slotta originally generated 
the antibody now commonly known as MAB3026 (AB_2178887) 
and provided its provenance: “It was transferred to Boehringer-
Mannheim as Clone 12H11, resold to Roche and finally bought by 
Chemicon, and it is now sold as MAB3026.” They then speculate 
that a mutation may have crept in at some point that altered the 
specificity of the antibody. However, the discrepancies may also 
be attributed to the additional testing of the antibody in new con-
ditions, revealing problems that had not been apparent during the 
initial applications. The authoritative Antibody Registry identifier 
(and therefore the RRID) for this antibody combines these different 
representations together so that all references to this antibody can 
be tracked. Authors are encouraged in the citation format to include 
details about the particular instance of this antibody, namely, the 
vendor from which the antibody was purchased and the catalog, 
batch, and lot numbers. However, we did not want to overload the 
ID system to require assignment of these different lot numbers dif-
ferent RRIDs and maintain the mappings. We were also concerned 
that this would grossly decrease compliance.
For organisms, all of the authors ‘errors’ were due to the allele being 
reported but not the organism stock or genotype. The allele ID is not 
sufficient for identifying the animal used as the same allele may be 
inserted into different mice of various backgrounds and with other 
alleles, and therefore will have different phenotypic characteristics. 
It should also be noted that authors consulting the MGI database 
(up to October 2014), which maintains the authoritative mouse 
nomenclature, would be able to search for a MGI identifiers for 
genes and alleles, but not genotypes. This shows that authors likely 
went to MGI to obtain their identifiers rather than searching the RII 
portal, but were not able to find the genotype information and sub-
stituted the allele ID. MGI now searches the genotype information 
for all mice suggesting that authors of newer papers can now also 
find the genotype information more easily at MGI and a tutorial for 
how to obtain a genotype identifier from MGI is now posted on the 
RII portal pages. Support for genotype identification, and therefore 
RRIDs, is planned to also be provided by a new Monarch Initia-
tive phenotyping tool for submission of genotype-phenotype data 
to journals and model organism databases.
For tools (software and databases), we elected to identify the root 
entity and not a granular citation of a particular software version 
or database. Our main goal in the case of software tools and data-
bases was to track broad patterns of utilization of these resources 
(e.g., how many times NeuroMorpho.org was used) and not particu-
lar versions. More complete practices for citing software and data 
sets are emerging from recent efforts like the Joint Declaration of 
Data Citation principles (https://www.force11.org/datacitation), the 
W3C HCLS dataset description (http://tiny.cc/hcls-datadesc), the 
software discovery index (http://softwarediscoveryindex.org/), and 
many others. These groups are exploring more complete reporting 
standards for the individual instances (versions, workflows, virtual 
machines) that can be used to reproduce the findings. We note that 
the goal of using RRIDs for software tools was to determine par-
ticipation rates for authors identifying these resources using the 
easiest possible solution, with the longer term goal including more 
robust versioning and archival software practices that would sup-
port reproducibility.
What are the next steps?
The RII is a grass-roots effort that took advantage of existing invest-
ments by the NIH to solve a problem without extensive new infra-
structure. The RII is continuing to run and has expanded beyond 
the initial participants. We believe that the growth of the initiative 
indicates that it fills a need not currently met by our existing prac-
tices and infrastructure.
Should RRIDs be adopted broadly across all of biomedicine? We 
would argue yes, the RRID syntax should become the standard for 
reporting on usage of research resources. We have shown that the 
requirements for this type of broad adoption are the availability of 
comprehensive and authoritative registries for the appropriate enti-
ties, a centralized portal or services that aggregate these registries 
into a single search, and the willingness of a community includ-
ing journals and publishers to support this type of reporting. More 
sophisticated services can be built to improve and automate author-
ing and editorial oversight, but these are not required. The solu-
tion is therefore accessible both to large commercial publishers and 
smaller community- or society-based journals.
If RRIDs were to be broadly adopted tomorrow, what are the out-
standing issues regarding implementation and scalability? The first 
issue is one of scope. The current RII focused on three types of 
research resources that were broadly used and a known source of 
variability within experiments. Should all research resources be 
similarly identified, i.e., every chemical, instrument, etc.? We think 
such an approach would be clumsy and difficult to implement. We 
can imagine a future where all reagents and tools are bar coded and 
scanned as they are used in a study. However, as long as humans are 
responsible for supplying identifiers, we think that the effort should 
focus on certain types of known problematic entities for which 
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better metadata and ability to query across papers is required. Given 
the recent problems associated with certain cell lines, for example, 
these are obvious candidates (ICLAC, 2014). The advantage of the 
current system is that it allows communities who have taken the 
steps to aggregate and organize resources that are of use to them to 
agree to include the RRID syntax and single entry point.
The second issue is governance. We deliberately designed a decen-
tralized system that gives control of issuing identifiers to multiple 
authorities. Such a model requires some governance, in the form of 
willingness of the authorities to maintain the integrity of any identi-
fiers and links and implementation of a policy regarding entities 
that are no longer available. We would also need some governance 
to ensure that multiple, uncoordinated authorities are not issuing 
IDs for the same research resource and that the IDs assigned to each 
entity are unique. The latter constraint is handled by the centralized 
aggregation service currently provided by SciCrunch, however it 
may be handled by other services in the future. Further, the RRID 
project promotes consistent citation of research resources at a first 
level identifiability. We believe that more granular reporting stand-
ards can and should work hand in hand with the RRIDs and could 
be coordinated with the authoritative communities, for example, 
versioned software releases in GitHub.
Some of these governance issues are necessarily interdependent 
on issues relating to sustainability. As we increase participation 
amongst journals and resource providers, it would make sense to 
spread the cost of maintenance and development. One thing to con-
sider is that resolution services can provide advertising for resource 
providers as third party applications are developed to connect peo-
ple to resources in different contexts (such as in the Elsevier appli-
cation described above). We would conjecture that as the number 
and types of these applications increase, the need to contribute and 
therefore help sustain resource registries will become increasingly 
advantageous.
We believe that the RRID project lays an important foundation for 
creating a type of “universal product code” (UPC) to help alert the 
scientific community when issues are raised about key research 
resources. Reagents and tools are not perfect and problems can arise, 
as the resources themselves can have issues as they are tested across 
various paradigms and systems. Even when a resource initially per-
formed well, due to spontaneous mutations in biological resources 
and interactions between particular software tools and platforms, 
problems can arise over time. For example, two recent papers have 
published extensive tests showing that common antibodies for NF-
κB show non-specificity under some circumstances (Listwak et al., 
2013;  Slotta et al., 2014). Many of these antibodies are extensively 
used in the literature, but readers of a particular article have no 
way of knowing that concerns have been raised. We have similar 
examples with software tools (Gronenschild et al., 2012), data sets 
(Button et al., 2013) (Hupé, 2015) and genetically modified animals 
(Cone et al., 2013). We have an infrastructure in place, CrossMark, 
to alert readers of a particular article that an addendum or erratum 
has been posted. The RRID system can serve as the basis for a 
similar system for research resources.
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Supplementary files
The goal of this document is to keep track of publications that have reported RRIDs and cross check the RRID, to ensure the authors are 
using the correct ID.
Click here to access the data.
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 William Gunn
Mendeley and the Reproducibility Initiative, Mountain View, CA, USA
The aim of this study was to determine the feasibility and utility of asking authors to include RRIDs when
submitting a manuscript. The process for making these determinations was well-considered and the
experience and professional relationships of the authors helped greatly in enabling the study to reach the
number of journals and submissions that it reached. The analysis of the data was described well and
carried out well, making it possible to replicate the experiment, in theory. As much of this study did
depend on professional relationships, it's not clear if it could be replicated in practice, but given the nature
of the study, this is expected. The authors are to be commended in particular for supplying the raw data
supporting the analysis in a usable form as supplementary data, This improved my understanding of the
work.
With regard to the 4 outcome measures (Compliance, Accuracy, Identifiability, and Utility) the scoring
method is clear and well-described, but I felt like there were some important aspects of the data that were
not addressed by the authors. With respect to compliance, it could be said that receiving 312 papers with
572 identifiers shows willingness to contribute, but the data in Table 2 suggest that reaching this level of
compliance required a very hands-on approach by the editors. This suggests that compliance may be
actually fairly hard to get. It's encouraging that 200 new antibody entries were created by authors, but it
would have been good to see more data on the prevalence of other resources.
With regard to the accuracy goal, a user study of a group of authors going through the workflow would
have a useful addition to the study to help determine where the trouble spots for authors arise. Are they in
the lookup on the SciCrunch portal or, as suggested for the case of MGI, at the registry itself?
The identifiability pre-pilot results are consistent with the results we reached in our analysis of the 
. The authors assert that authors are able to performReproducibility Project: Cancer Biology set of papers
the task accurately for software tools, but it is worth noting that software tools had low identifiability before
and improved the least. Some discussion about why that is the case would be useful.
Regarding utility, evidence is presented that RRIDs are highly useful because an RRID can be entered
into Google Scholar and a link to a paper mentioning that RRID can be retrieved. This is perhaps the
weakest part of the study, because the utility criteria were that a query could be constructed to show all
the publications in which the resource were used could be found. They report data that only 174 identifiers
could be found in Google Scholar, but it's not clear how this data was obtained, not exactly what the
numbers refer to. The exact query used for each search index should be supplied & the results
themselves should have been stored. Given the lack of detail around these points, it's hard to judge if it's
actually possible to conduct these queries in a systematic fashion. The discussion about the failure of
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themselves should have been stored. Given the lack of detail around these points, it's hard to judge if it's
actually possible to conduct these queries in a systematic fashion. The discussion about the failure of
researchers to include RRIDs in a consistent form shows the current method to get RRIDs inserted in the
literature is not sufficient for widespread use, and the level of support required by the SciCrunch site
maintainers (100 queries for 10000 searches) also suggests that this approach would not scale. Given the
lack of an API for Google Scholar, the approach used is understandable, and it's noted that the RRID
Resolver page at SciCrunch does link to a PubMed query for papers mentioning the resource, but there is
a text mining API available for ScienceDirect papers which would have been a better choice for assessing
presence in ScienceDirect. Overall, the study would have been improved by the addition of a data
scientist & must be judged to have failed on the utility criteria as established. This doesn't mean RRIDs
are shown not to be useful; on the contrary, it's clear that RRIDs do allow a researcher to find the actual
resource used, so in that respect they're quite useful indeed and the resolver page is very helpful. There's
a case for broader utility to be made, as well, with the example of the "Antibody data for this article" article
enhancement on ScienceDirect.
It would also have been useful to see a more extended discussion of the sustainability of this project. For
example, are journals to take this on as a means to add value, and if so, who pays for the maintenance of
the SciCrunch resolver?
Overall, the authors have presented good quality data on the feasibility and usability of asking authors to
contribute RRIDs to publications and the publishing community should consider this study when
considering ways to enrich the literature for text and data mining purposes.
The takeaways for me are:
Just asking authors via the information for authors pages or via one-off emails does not work.
Letting authors enter RRIDs manually detracts from the utility of the identifiers. There's a big opportunity
for machine learning approaches here to identify and suggest RRIDs at submission.
Non-open access articles inhibit research by preventing the full-text indexing of their articles by search
indexes.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 I am co-founder of the Reproducibility Initiative, so I'm favorably inclined towardsCompeting Interests:
anything that looks to improve reproducibility. I also work for Mendeley, a service for researchers which is
engaged in text and data mining of literature. Mendeley is owned by Elsevier, which developed the
'Antibody data from this article" widget shown as an example in this paper.
 05 June 2015Referee Report
doi:10.5256/f1000research.7039.r8814
 Randi Vita
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
This manuscript is overall well written with an appropriate title. The abstract provides an adequate
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This manuscript is overall well written with an appropriate title. The abstract provides an adequate
summary and the design and explanation are sound. I believe the conclusions are justified and the data
provided is adequate to support them. The subject is valuable to many researchers and provides an
important service to researchers going forward. I have a few minor grammatical issues to report:
The sentence "The pilot project has focused on a limited number of resources - antibodies,
software tools/databases, and model organisms" should be "The pilot project focused on a limited
number of resources..."
 
in "accession number, as Genbank does for gene" should use "GenBank"
 
For sentence "Over the minimum 3-month window, each partner journal would request that authors
supply RRIDs in a standard format as a citation to indicate the use of any of these three types of
research resources."
In this context, what the "three types of research resources" are is unclear.
 
The sentence "As these papers start to appear in PubMed Central where there is full text search, it
should be possible to find papers for RRIDs through the National Library of Medicine." is a little
confusing, maybe "As these papers start to appear in PubMed Central, where full text search is
possible, papers utilizing RRIDs will be identifiable through the National Library of Medicine." is
better? Yes, being  overly nit picky, but I had to read it twice to get it.
 
Verb tense should be reviewed throughout the manuscript to ensure consistency.
 
Uses of dashes such as "...from vendors - both solicited and unsolicited - and at.." occurs
throughout the manuscript. This seems nonstandard?
 
In Figure 3, I could not see the pre-pilot bar. This could be due to something with my browser, but
worth checking out.
 
In the Discussion, the sentence "The pilot RRID project has been highly successful in
demonstrating the utility of a system to aid in identification of these three research resources in the
literature" should reiterate what three research resources it is referring to.
 
Review the number of uses of the word "however" and how close to each other they occur. For
example, "However, authors are encouraged in the citation format to include details about the
particular instance of this antibody, namely, the vendor from which the antibody was purchased
and the catalog, batch, and lot numbers. However, we..."
And lastly, the link referred to here "A list of the participating journals is available on the Force11 website (
)." did not provide a list of the multiple immunology journals in thehttps://www.force11.org/RII/SignUp
Elsevier family that are participating. The page just shows the Elsevier logo.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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